WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406120
Description: RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.
MedKoo Cat#: 406120
Chemical Formula: C15H14BrClN2O4S
Exact Mass: 431.95462
Molecular Weight: 433.7
Elemental Analysis: C, 41.54; H, 3.25; Br, 18.42; Cl, 8.17; N, 6.46; O, 14.76; S, 7.39
Synonym: RKS262; RKS 262; RKS-262
IUPAC/Chemical Name: (E)-6-bromo-4-chloro-3-(((3-methyl-1,1-dioxidothiomorpholino)imino)methyl)-2H-chromen-2-one
SMILES Code: O=C1C(/C=N/N(CC2)C(C)CS2(=O)=O)=C(Cl)C3=C(O1)C=CC(Br)=C3
1: Singh RK, Dorf L, DeMartino A, Illenye S, Koto K, Currier EA, Ashikaga T, Kim KK, Brard L, Sholler GL. Oral RKS262 reduces tumor burden in a neuroblastoma xenograft animal model and mediates cytotoxicity through SAPK/JNK and ROS activation in vitro. Cancer Biol Ther. 2011 Jun 15;11(12):1036-45. Epub 2011 Jun 15. PubMed PMID: 21532338.